Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Inclusion Criteria: * Female patients with breast cancer either in the primary or metastatic setting * Tumor must be estrogen receptor and/or progesterone receptor positive and Her-2 negative * Evidence of disease resistance to an aromatase inhibitor * ECOG performance status 0 or 1 * Age 18 years or older * Adequate laboratory values * Able to give written informed consent * Measurable disease * No more than 2 prior chemotherapy regimens in the metastatic setting * Unlimited prior hormonal therapy in the metastatic setting * Life expectancy of greater than 3 months * Post-menopausal * Tumor must be available for central testing for FGFR1 amplification by FISH/CISH Exclusion Criteria: * Brain metastases * Another primary malignancy within 3 years prior to starting drug therapy with the exception of adequately treated in-site carcinoma of the uterine cervix or skin cancer * Chemotherapy within 3 weeks prior to starting study drug or not recovered from side effects of previous therapy * Administration of nitrosurea or mitomycin-C within 6 weeks prior to starting study drug or not recovered from side effects of such therapy * Administration of biologic therapy within 6 weeks prior to starting study drug or not recovered from side effects of such therapy * Radiotherapy within 4 weeks prior to starting study drug or 2 weeks in the case of localized radiotherapy or not recovered from radiotherapy toxicities * major surgery, open biopsy or significant traumatic injury within 4 weeks prior to starting study drug or a minor procedure, percutaneous biopsy or placement of a vascular access device within 1 week prior to starting study drug or not recovered from side effects of such procedure or injury * Chronic concomitant bisphosphonate therapy for the prevention of bone metastases. Bisphosphonate/ denosumab therapy for the management of bone metastases or for the treatment of osteoporosis s allowed. * Impaired cardiac function or clinically significant cardiac disease * Impairment of GI function or GI disease that may significantly alter the absorption of dovitinib * Cirrhosis, chronic active hepatitis, or chronic persistent hepatitis * Known diagnosis of HIV infection * Anticoagulation treatment with therapeutic doses of warfarin * Any concurrent severe and/or uncontrolled concomitant medical condition that could cause unacceptable safety risks or compromise compliance with the protocol * Pregnant or breast-feeding * Unwilling or unable to comply with the protocol